Psychedelics Startups

Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.

11 investors